Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 18 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Forward Industries Inc. (NASDAQ: FWDI) Optimizes Capital Strategy with Strategic Buyback
Forward Industries (NASDAQ: FWDI) builds, operates, and manages a large-scale Solana (SOL) treasury, and is backed…
-
QualityStocksNewsBreaks – Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) Delineates High-Priority REE Zones at Atikokan
Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising. Powermax Minerals (CSE:…
-
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Advancing Early Detection, Tackling Heart Disease Through AI and Biomarker Insights
The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential.…